(Q39519074)

12 September 2017

title

Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1. (English)

1 reference

12 September 2017

L W Wood

1

1 reference

12 September 2017

E J Shillitoe

series ordinal

2

1 reference

12 September 2017

publication date

24 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

18

1 reference

12 September 2017

issue

10

1 reference

12 September 2017

page(s)

685-694

1 reference

An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

ReVOLT: radiation-enhanced viral oncolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

The role of viral and host genes in corneal infection with herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Herpes simplex virus blocks apoptosis by precluding mitochondrial cytochrome c release independent of caspase activation in infected human epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Viral oncoapoptosis of human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Caspase 3 activation during herpes simplex virus 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Herpes simplex virus type 1 immediate-early gene expression is required for the induction of apoptosis in human epithelial HEp-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Rapid simultaneous determination of apoptosis, necrosis, and viability in sulfur mustard exposed HaCaT cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Caspase inhibitors promote alternative cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Mutations that increase DNA binding by the processivity factor of herpes simplex virus affect virus production and DNA replication fidelity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Identification of structural components associated with cytostatic activity in MCF-7 but not in MDA-MB-231 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Autophagic cell death unraveled: Pharmacological inhibition of apoptosis and autophagy enables necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Pathways leading to apoptotic neurodegeneration following trauma to the developing rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

7 January 2021

Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207).

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

7 January 2021

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

7 January 2021

Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.34

7 January 2021

Identifiers

DOI

10.1038/CGT.2011.34

1 reference

12 September 2017

1 reference